Genomic Health, a life science company focused on the development of genomic-based clinical diagnostic tests for cancer, announced Friday morning that it will offer 5.0 million shares at a range of $12-$14. Assuming the stock prices at the midpoint, the company will have an initial market capitalization of $316 million. JP Morgan and Lehman Brothers will be the joint book runners on the deal. Timing has yet to be determined.
